Prospective observational study to further understand the value that a multi-omic approach has in individuals with a multi system, early onset disorder that does not have a molecular diagnosis by whole genome sequencing.
Current status: Unknown.
Illumina Inc (ILMN) is the sponsoring company for this trial. BiotechSign currently grades this company F (25/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.